Investor · 1 deal
Every published round StatewideSuper took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies StatewideSuper has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| ENA Respiratory | Antiviral nasal spray to prevent severe respiratory viral infections | 27 Sep 2020, Series A | 1 | 0 |
This is a stake in the fund itself, money that the fund's manager invests, not a stake in the fund manager.
Companies StatewideSuper has backed that another company then bought. An exit for the holding, not a deal StatewideSuper did.
Stories naming StatewideSuper. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sydney venture firm AirTree has raised A$700 million across three vehicles — an early-stage fund, a web3 fund and a growth fund — with superannuation funds as backers. Its portfolio includes Canva, Linktree and Immutable.
Also Startup Daily·TechCrunch Venture·Startup Daily·Startup Daily·Startup Daily
Ferret research found Ena Respiratory's INNA-051 nasal spray sharply lowered coronavirus levels; the biotech has banked an $11.7 million Series A and aims to begin human trials within months.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio
Brandon Capital's blog reports a first close of $210 million toward its $250 million MRCF 5 biotech fund, with super funds and CSL backing, and recalls past portfolio sales of Spinifex and Fibrotech.
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily